公开(公告)号：US09694054B2

公开(公告)日：2017-07-04

申请号：US14877354

申请日：2015-10-07

申请人： Mallinckrodt Pharma IP Trading D.A.C.

发明人： Joseph Grimbergen ,  Jacob Koopman ,  Abraham Bout

IPC分类号： C12Q1/56 ,  C12P21/04 ,  A61K38/00 ,  C07K14/75 ,  A61K38/36 ,  C12P21/00

CPC分类号： A61K38/363 ,  A61K38/4833 ,  C07K14/75 ,  C12P21/005 ,  A61K2300/00

摘要： The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen.

公开(公告)号：US09689881B2

公开(公告)日：2017-06-27

申请号：US13822209

申请日：2011-09-15

申请人： Amar Rida ,  Nicolas Mermod ,  Patrice Francois ,  Vladimir Lazarevic ,  Jacques Schrenzel

发明人： Amar Rida ,  Nicolas Mermod ,  Patrice Francois ,  Vladimir Lazarevic ,  Jacques Schrenzel

IPC分类号： G01N33/86 ,  G01N33/569 ,  C12Q1/56

CPC分类号： G01N33/86 ,  C12Q1/56 ,  G01N33/56938 ,  G01N2333/75 ,  G01N2333/974

摘要： A method for separating target molecules or particles from a fibrinogen containing sample comprises: (a) trapping the said target molecules or particles in a fibrin network by converting at least partially the fibrinogen contained in the sample into fibrin; (b) retracting the said fibrin network to form a fibrin clot; (c) separating the said fibrin clot from the surrounding sample medium.

公开(公告)号：US09624528B2

公开(公告)日：2017-04-18

申请号：US14918413

申请日：2015-10-20

申请人： Abbott Cardiovascular Systems Inc.

发明人： Mirna Koscec ,  Eugen Koren

IPC分类号： C12Q1/56 ,  C12Q1/32 ,  G01N33/86

CPC分类号： C12Q1/56 ,  C12Q1/32 ,  G01N33/86 ,  G01N2333/904

摘要： A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined.

公开(公告)号：US09381232B2

公开(公告)日：2016-07-05

申请号：US14551332

申请日：2014-11-24

申请人： BAE Systems Information and Electronic Systems Integration Inc.

发明人： Robert A. Burton

IPC分类号： A61K38/36 ,  C07K14/75 ,  C12Q1/56 ,  A61K47/48

CPC分类号： A61K38/363 ,  A61K47/6923 ,  A61K47/6935 ,  C07K14/75 ,  C12Q1/56

摘要： A fibrin-based hemostatic agent suitable for both civilian and military use is disclosed. The hemostatic agent comprises (i) nanoparticles to which a plurality of Knob-A recognition sequences are attached, and (ii) coiled-coils of recombinantly-produced human fibrinogen α and chains and the γ chain globular domain. A delivery system for the hemostatic agent also is disclosed, which additionally comprises means for delivering (i) and (ii) to a wound site. The delivery means may be a CO2 canister or a shaker jet.

摘要翻译： 公开了适用于民用和军用的基于纤维蛋白的止血剂。 止血剂包括（i）附着有多个Knob-A识别序列的纳米颗粒，和（ii）重组产生的人纤维蛋白原α和链的线圈和γ链球形结构域。 还公开了止血剂的递送系统，其还包括用于将（i）和（ii）递送到伤口部位的装置。 输送装置可以是CO 2罐或振荡器喷嘴。

公开(公告)号：US09329192B2

公开(公告)日：2016-05-03

申请号：US13026474

申请日：2011-02-14

申请人： Hans-Jurgen Kolde ,  Ute Lange ,  Elke Bucha

发明人： Hans-Jurgen Kolde ,  Ute Lange ,  Elke Bucha

IPC分类号： C12Q1/56 ,  G01N33/86 ,  C12N9/74 ,  C12N9/64

CPC分类号： G01N33/86 ,  C12N9/6429 ,  C12N9/647 ,  C12Y304/21005

摘要： The present invention is directed to a simple process for the modification of the specificity of a peptidase of the hemostatic system by coupling polymers to the peptidase causing it to lose its reactivity in the hemostatic system, but enabling it to continue to react with certain inhibitors, effectors and substrates. The invention is furthermore directed to processes for the detection or quantitative determination of inhibitors of the peptidase in bodily fluids or other samples as well as to processes for their neutralization and/or removal from liquids. Finally, the invention allows the use of a polymer-coupled peptidase as drug and furthermore provides a device which makes use of such a peptidase in the removal of peptidase inhibitors from samples or from the bloodstream of a patient.

摘要翻译： 本发明涉及通过将聚合物偶联至肽酶来改变止血系统肽酶的特异性的简单方法，导致其在止血系统中失去其反应性，但使其能够与某些抑制剂继续反应， 效应器和基板。 本发明还涉及用于检测或定量测定体液或其它样品中肽酶抑制剂的方法，以及其中和和/或从液体中除去的方法。 最后，本发明允许使用聚合物偶联的肽酶作为药物，并且还提供一种使用这种肽酶从样品或来自患者的血液中除去肽酶抑制剂的装置。

公开(公告)号：US09291612B2

公开(公告)日：2016-03-22

申请号：US13632393

申请日：2012-10-01

申请人： Micropoint Bioscience, Inc.

发明人： Pingyi Yan ,  Haitao Huang ,  Shenyu Wang ,  Huihui Lu

IPC分类号： G01N33/48 ,  G01N33/49 ,  G01N33/86 ,  C12Q1/56 ,  G01N27/26

CPC分类号： G01N33/4905 ,  C12Q1/56 ,  G01N33/86

摘要： In some examples, a device applies an electrical potential difference across a blood sample. The device measures an electrical signal that passes through the blood sample over a duration of time to obtain a plurality of measurements representing a measurement function of time. An accumulative property of the measurement function may be determined such that the accumulative property correlates to a blood coagulation characteristic.

摘要翻译： 在一些示例中，装置在血液样本上施加电势差。 该装置测量在一段时间内通过血液样本的电信号，以获得表示时间的测量功能的多个测量值。 可以确定测量功能的累积特性，使得累积特性与凝血特性相关。

公开(公告)号：US20160032355A1

公开(公告)日：2016-02-04

申请号：US14813939

申请日：2015-07-30

申请人： Haemonetics Corporation

发明人： Fowzia S. Zaman ,  Marc Doubleday

IPC分类号： C12Q1/56

CPC分类号： C12Q1/56 ,  G01N33/86 ,  G01N2333/96444

摘要： In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.

摘要翻译： 在一些实施方案中，本发明提供了用于检测和/或分类患者治疗相关量或更高抗凝血剂的方法，包括使对照血液成分（已知不含有抗凝血剂的已知物）的样品在凝血测定中 存在因子Xa试剂以获得对照凝血测量; 并且在因子Xa试剂存在下对疑似患有抗凝血剂的患者的血液成分样品进行凝血测定以获得患者凝血测量，其中大于对照凝血测量的患者凝血测量样品表明存在 的抗凝血剂在患者的治疗相关量或更高。 在一些实施方案中，本发明包括使用在ecarin试剂存在下使用凝血测定法将抗凝血剂分类为抗因子Xa或直接凝血酶抑制剂抗凝血剂的方法。

公开(公告)号：US09241958B2

公开(公告)日：2016-01-26

申请号：US14168195

申请日：2014-01-30

申请人： The Board of Trustees of the University of Illinois

发明人： Stephanie A. Smith ,  James H. Morrissey

IPC分类号： A61K33/42 ,  A61P7/04 ,  C12Q1/56 ,  G01N33/86 ,  A61K38/36

CPC分类号： A61K33/42 ,  A61K38/36 ,  C12Q1/56 ,  G01N33/86

摘要： A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient.

摘要翻译： 用于治疗凝血缺乏患者的方法包括向患者施用足量的polyP量以降低患者血浆的PT测试值或稀释PT测试值。

公开(公告)号：US20150369829A1

公开(公告)日：2015-12-24

申请号：US14842388

申请日：2015-09-01

申请人： T2 Biosystems, Inc.

发明人： Sonia TAKTAK ,  Brian M. MOZELESKI ,  Thomas J. LOWERY, Jr.

IPC分类号： G01N33/86 ,  G01N24/08 ,  C12Q1/56

CPC分类号： G01N33/86 ,  C12Q1/56 ,  G01N24/088 ,  G01N33/48 ,  G01N33/483 ,  G01N33/487 ,  G01N33/4905 ,  G01R33/465 ,  G01R33/50 ,  G01R33/5617

摘要： The invention relates to detecting coagulation and coagulation-related activities including agglutination and fibrinolysis of samples. More particularly the invention relates to methods and apparatus for monitoring coagulation and/or obtaining a coagulation time of a sample using NMR-based detectors.

摘要翻译： 本发明涉及检测凝血和凝血相关活性，包括样品的凝集和纤维蛋白溶解。 更具体地，本发明涉及用于使用基于NMR的检测器来监测凝固和/或获得样品的凝固时间的方法和装置。

公开(公告)号：US20150344935A1

公开(公告)日：2015-12-03

申请号：US14823450

申请日：2015-08-11

申请人： RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

发明人： Job Harenberg ,  Roland Krämer

IPC分类号： C12Q1/56

CPC分类号： G01N33/86 ,  C12Q1/56 ,  G01N33/58 ,  G01N2333/811 ,  G01N2333/96444 ,  G01N2458/30

摘要： The present invention relates to a method for detecting at least one direct factor Xa inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a factor Xa inhibitor with a composition containing factor Xa under conditions which allow the factor Xa to release a detectable substance from a chromogenic substrate.

摘要翻译： 本发明涉及一种用于检测除了柠檬酸盐血浆以外的样品中的至少一种直接因子Xa抑制剂的方法，其包括以下步骤：将含有因子Xa抑制剂的样品与含有因子Xa的组合物混合在允许因子Xa 从显色底物释放可检测物质。